Last update 21 Nov 2024

Gadoterate Meglumine

Overview

Basic Info

Drug Type
Contrast agent, Small molecule drug
Synonyms
DOTA-Gd meglumine, DOTA-gadolinium meglumine, GD-DOTA
+ [16]
Target-
Mechanism
Magnetic resonance imaging enhancers
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (22 Sep 2000),
Regulation-
Login to view timeline

Structure

Molecular FormulaC23H42GdN5O13
InChIKeyRYHQMKVRYNEBNJ-BMWGJIJESA-K
CAS Registry92943-93-6
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Vascular Diseases
US
20 Mar 2013
Contrast agents
JP
22 Sep 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
vascular arterial diseasePhase 2
US
01 Apr 2009
Central Nervous System DiseasesPhase 1
BR
01 Sep 2010
Central Nervous System DiseasesPhase 1
GB
01 Sep 2010
Central Nervous System DiseasesPhase 1
DE
01 Sep 2010
Central Nervous System DiseasesPhase 1
IT
01 Sep 2010
Central Nervous System DiseasesPhase 1
CL
01 Sep 2010
Central Nervous System DiseasesPhase 1
AR
01 Sep 2010
Central Nervous System DiseasesPhase 1
KR
01 Sep 2010
Cerebral Arterial DiseasesPhase 1
US
01 Oct 2009
Renal Artery ObstructionPhase 1
US
01 Apr 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
37
xplcbcboxf(rcjplgkkac) = twuoeurstv lchbrwyyyn (quwjdifrsf, nlphcguabk - amewecttuz)
-
08 Aug 2019
Phase 4
-
51
rzjayetumz(kpdeuhmcrp) = tgzygccudl gttpizfsly (jzwjgxeyth, gdhzjyhywk - htqivvlbmz)
-
09 Mar 2017
Phase 4
179
(MultiHance 0.1 mmol/kg Arm (Reader 1))
sldzwikddv(mjdqhtnusg) = arktsliiyz vtdacpbrar (ubevsefglu, ahpibxgrqz - akxukncutq)
-
10 Jan 2017
(MultiHance 0.1 mmol/kg Arm (Reader 2))
sldzwikddv(mjdqhtnusg) = nacslmouzc vtdacpbrar (ubevsefglu, pjkdjsgobb - horjpepmbx)
Phase 3
416
(Dotarem (Gadoterate Meglumine ))
cxllztdkhn(iwpffusbeb) = saqagwlsrd cqvqauibpb (defthjkwuk, bhjxkokbub - rpadhvprec)
-
29 May 2014
(Magnevist (Gadopentetate Dimeglumine))
cxllztdkhn(iwpffusbeb) = vdejwwwlmj cqvqauibpb (defthjkwuk, suqhoaxisj - gtbjucsolb)
Phase 4
189
Gadovist
(Gadovist)
xgzydvvkle(khzichxxkd) = erpnwferor univonmsab (sbgiodraft, madrucnoux - mrklzorynh)
-
11 Dec 2012
(Dotarem, Interventional)
xgzydvvkle(khzichxxkd) = fnynwykkem univonmsab (sbgiodraft, mmzbczjqmt - zgfbjzbjgz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free